key: cord-0961958-sg26bwiv
authors: Fröberg, J.; Gillard, J.; Philipsen, R.; Lanke, K.; Rust, J.; van Tuijl, D.; Bousema, T.; Simonetti, E.; van der Gaast-de Jongh, C.; Bos, M.; van Kuppeveld, F. J. M.; Bosch, B. J.; Nabuurs-Franssen, M.; van der Geest-Blankert, N.; van Daal, C.; Huynen, M. A.; de Jonge, M. I.; Diavatopoulos, D. A.
title: Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms
date: 2021-02-03
journal: nan
DOI: 10.1101/2021.02.02.21250910
sha: 87c42e31dab5600e316debec7c2b777fe3463299
doc_id: 961958
cord_uid: sg26bwiv

Mucosal antibodies play a key role in protection against SARS-CoV-2 exposure, but their role during primary infection is not well understood. We assessed mucosal antibody responses during primary infection with SARS-CoV-2 and examined their relationship with viral load and clinical symptoms. Elevated mucosal IgM was associated with lower viral load. RBD and viral spike protein-specific mucosal antibodies were correlated with decreases in systemic symptoms, while older age was associated with an increase in respiratory symptoms. Up to 42% of household contacts developed SARS-CoV-2-specific mucosal antibodies, including children, indicating high transmission rates within households in which children might play an important role.

Transmission within households is an important contributor to the spread of SARS-CoV-2, as close 36 contact within households facilitates early-onset pre-symptomatic transmission of the virus. [1] [2] [3] The 37 rapid spread of SARS-CoV-2 in populations is attributed to several aspects of the virus, i.e. route of 38 transmission via respiratory droplets, rapid viral replication and shedding from the upper-respiratory 39 tract 4 , early infectiousness with a peak viral load before onset of symptoms 5,6 , and a high frequency of 40 mild and asymptomatic infections 6-10 . These aspects make controlling the outbreak difficult, as current 41 control strategies are primarily dependent on symptomatic case detection 11, 12 . Additionally, they 42 indicate a high probability that pre-symptomatic carriers are important drivers of community-based 43 transmission of the virus 11, 13 . The role of children in transmission remains a highly debated subject, as 44 children often develop asymptomatic or atypical disease which makes them prone to 45 underdiagnosis 3, 9, 14 . A better understanding of the virology, immunology and clinical symptoms of 46 mild SARS-CoV-2 infections in a community setting is therefore essential to track the spread of 47 SARS-CoV-2 in the general population, and to inform intervention measures. shares approximately 80% of its amino acid sequence with SARS-CoV-1 and other seasonal 56 coronaviruses 17 . Therefore, pre-existing immunity against the N-protein may play a protective role 57 during infection 17, 18 . Studies investigating antibody response dynamics in mild cases have 58 demonstrated the development of serum antibodies against SARS-CoV-2 approximately 10-15 days 59 post symptom onset 4, 19 . Relevance of serum antibodies to protection of severe disease is however 60 equivocal, as some studies found that the antibody response in mild infections is transient 20,21 , while 61 others reported robust and long-lasting antibody responses following mild infections 22, 23 . 62

The recruitment strategy for inclusion of households focused on healthcare workers with a PCR-87 confirmed infection who were in home isolation (index cases) with at least two participating 88 household members. Between 26 March 2020 and 15 April 2020, we enrolled 50 index cases and 137 89 household members (Figures 1a and b) . Home visits were planned to collect naso and oropharyngeal 90 swab samples and nasal mucosal lining fluids (MLF) on the day of study enrolment (D0). In addition, 91

MLFs were self-sampled on three subsequent timepoints and a serum sample was collected on the last 92 day of the study. Index cases were asked to report their first day of symptoms, and all volunteers were 93 asked to complete a daily symptom survey in order to monitor disease progression (Figure 1c) . The 94 analysis of mucosal antibody responses was compared with viral load, serological and symptom data. 95

The general characteristics of study participants are shown in Table S1 . Index cases were mostly 96

To examine the relationship between mucosal antibodies and virologic and clinical features, we 123 focused on the index cases (n=50), as this group reported a date of symptom start. All index cases 124 were included within two weeks of first experiencing symptoms ( Figure S2a) , and all data of the 125 index cases were collected between 0 and 40 days post symptom onset (PSO) (Figure S2b) , making 126 the index cases a suitable cohort to examine these relationships during the acute phase of COVID-19 127 disease. The viral load at study enrolment was non-significantly lower when the individual had a 128 longer period of symptoms before study start (Figure s3) . We correlated MLF antibody measurements 129 collected at study start with viral load and the days since symptom onset. A higher mucosal IgA 130 antibody level at enrolment was correlated with a longer period of symptoms before study start, while 131 viral load was negatively correlated with IgM levels specific for RBD and S antigens (Figure 3a) . 132

This correlation pattern persisted after adjusting for age, sex, days since symptom onset for the viral 133 load correlation, and viral load for the days since symptom onset correlation (data not shown). 134

To examine the kinetics of the mucosal antibody response, we measured the magnitude of antibody 136 responses in the mucosal lining fluid of index cases at study day 0, 3, 6, and 28. Previous studies have 137

shown that coronavirus-specific antibodies are significantly elevated in serum around two weeks PSO 138 26, 27, 29 . We examined longitudinal mucosal antibody responses by binning samples into three-day 139 timeframes relative to the day of symptom onset and plotting the values alongside controls. Mucosal 140 IgM, IgA, and IgG antibody levels for S and RBD antigens were significantly elevated relative to 141 controls between 7-9 days PSO and remained high up to 40 days PSO, while for N protein only IgG 142 antibody responses were significantly higher than controls after 28 days PSO (Figure 3b) . 143

In order to study the temporal changes in the relationship between the antibody-antigen types, we 144 calculated correlations among antibody responses within each timeframe. While IgA, IgG and IgM 145 isotypes were highly intercorrelated between S and RBD near the start of symptom onset, at the final 146 measurement (28+ days POS) correlations between the IgA-S and IgA-RBD isotype were much 147 weaker. Correlations of N-protein antibodies with S and RBD were overall weaker until at least two 148 weeks PSO, at which point the IgG-N response correlated with the IgG-RBD and IgG-S antibody 149 measurements (Figure 3c) . 150

Thus, SARS-CoV-2 infection induces a robust IgA, IgG, and IgM mucosal antibody response 151 primarily against the S and RBD antigens as early as 7-9 days post symptom onset, while antibodies 152 against N-protein show a different, slower induction and are overall restricted to IgG. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

Mild COVID-19 disease is highly variable in its presentation and is generally characterized as a 157 SARS-CoV-2 infection that does not require hospitalization or oxygen support and is not accompanied 158 by severe symptoms like pneumonia 4, 8, 30 . We examined the progression of 23 symptoms using a 159 survey that all volunteers filled in daily throughout the follow-up. To analyse the clinical 160 manifestation of mild COVID-19 disease over a period soon after symptom onset, we focused on the 161 index cases. The most frequently reported symptoms across the entire study period were fatigue, 162 rhinorrhea, coughing, headache, and anosmia ( Figure S4a ). In order to compare different aspects of 163 the clinical presentation, we grouped the symptoms into three categories: gastrointestinal symptoms 164 (GS), systemic disease symptoms (SDS) and respiratory symptoms (RS). All index cases reported 165 symptoms at the start of the study (Figure S4b) . Fatigue was reported very frequently, and as such 166

was not categorized ( Figure S4a and b) . We examined whether the symptom duration varied between 167 different clinical presentations, and calculated the duration for each index case for each symptom 168 group. The duration of SDS was significantly shorter than RS, and by the end of the study period 169 nearly all index cases had resolved their SDS, while a quarter still reported RS ( Figure S4c ). To 170 examine longitudinal changes in the magnitude of COVID-19 symptoms, we binned symptom 171 notifications into three-day timeframes relative to the day of symptom onset, similar to the antibody 172 analysis. While the number of SDS rapidly decreased from the time of symptom onset, RS appeared to 173 stay high for at least two weeks post symptom onset (Figure 4a ). We investigated if patient 174 characteristics were associated with changes in symptoms over time. We constructed a linear mixed-175 effects model per symptom group with the number of reported symptoms as the response and time 176 since symptom onset, age, and sex as covariates. Such a linear model was a good fit for our 177 longitudinal symptom data ( Figure S5 ). While time was significantly associated with decreases in 178 symptoms, age was significantly associated with increased RS when correcting for the effect of time 179 (p-value = 0.0165, Figure 4b) . The sex had no effect on any symptom response group. To ascertain 180 whether the induction of mucosal antibodies was associated with COVID-19 symptoms, the 181 longitudinal mucosal antibody measures were added to the model in a univariate manner. This way, 182 estimated changes in symptoms per unit increase of antibody signal represent the additional effect of 183 antibodies while controlling for time, age, and sex. Increases in mucosal antibodies overall were 184 associated with decreased SDS and RS. A significant association was only found for SDS, where high 185 levels of IgM and IgG for S and all isotypes for RBD were related to a decrease in symptoms. The 186 largest effect was seen in the relation between IgA-RBD and SDS (Figure 4c) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021.

To examine infections amongst household clusters, we classified household contacts into cases or non-191 cases. Cases were classified first by their PCR result on enrolment, followed by seroconversion for 192 one of the antibody isotypes against S-protein and mucosal antibody responses against S-protein at the 193 end of the follow-up. The PCR positive threshold was set at a Ct value <36, corresponding to a viral 194 load of ≥10 3 copies/ml. The seroconversion threshold was based on the mean + 2*SD of the log2-195 transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal antibodies against 196 S, we used a naive Bayes model that was trained by the mucosal antibody measurements of the PCR 197 positive study participants (cases) and the pre-SARS-CoV-2 control samples (controls). Together, this 198 approach identified 75 cases amongst 137 (54.7%) household contacts (Figure 5a) , of whom 64% 199

were PCR positive at study start, 87% were seropositive at the end of the follow-up, and 76% were 200 identified as a case based on the MLF antibody levels at the end of follow-up (table S2). The majority 201 of PCR positive cases also developed serum and MLF antibodies at the end of the study (88%). By 202 including antibody measurements, 27 additional cases were identified (36% of cases). 203

All participants were asked if they were the first with COVID-19 related symptoms (primary case) in 205 the household (parents were asked to answer for young children). This classification was solely based 206 on symptoms, as only healthcare workers were eligible for PCR testing at the time of this study. 207

Among the contacts included in the study, nine were reported to be the primary case based on the 208 timing of symptom onset. When we correlated their mucosal antibody responses to viral load, a similar 209 negative correlation of IgM levels with viral load was observed for the S and RBD antigens as in the 210 index cases (Figure 5b ). We hypothesized that the primary cases within the household contacts would 211 have been symptomatic for a longer period than the non-primary contacts. To see if this different stage 212 of infection would be reflected in a difference in mucosal antibody levels, we plotted their mucosal 213 antibody values in a similar manner as the index cases, using the day of symptom onset of the index 214 case in the respective household as we did not have this data for the contacts. We found that primary 215 cases, compared to secondary cases, had earlier and overall higher antibody responses for all antibody 216 isotypes of S and RBD antigens (Figure 5b) . Similar to the index cases, IgM and IgA antibody 217 responses against the N-protein were relatively weak and were in range of the pre-SARS-CoV-2 218 control samples. 219

The role of children in transmission of SARS-CoV-2 has been the subject of significant discussion. 220

We therefore examined the likelihood that children <12y become infected. We found that 16 of the 33 221 (48.5%) of the children <12y were infected, which was not significantly different compared to the 222 59/104 (53.8%) in the >12y household contacts (p-value:0.78, Figure 6a ). In the contacts above 50 223 years, the proportion of infection was the highest (19/ 31, 61%). Most of these infected contacts above 224 50 years were the partner of the index case (12/19, 63%), while all infected participants <12y were 225 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint children of the index case. Of note, 29% of all infected household members did not have any 226 symptoms at study start, and 19% of all infeceted contacts remained asymptomatic throughout the 227 entire follow-up. When examining the distribution of asymptomatic cases among the four age groups, 228

we found that 7 out of the 16 (44%) cases <12y were asymptomatic at study start, compared to 11 of 229 the 59 (20%) cases above 12y (p-value:0.10, Figure 6b ). When we examined the overall number of 230 symptoms that was reported throughout the follow-up, we noticed a strong and significant positive 231 correlation between number of symptoms and age (Figure 6c) . Despite the lower number of 232 symptoms or absence of symptoms in child cases, no differences were found in viral load compared to 233 the older age categories, nor were the serum antibody levels at the end of the follow-up different 234 between the age-groups (Figure s6a and b) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint

In this study, we examined the mucosal antibody responses following infection with SARS-CoV-2 and 240 the development of mild COVID-19 disease in 50 adults and their household contacts. This study 241 demonstrates the unique value of using mucosal lining fluid to assess various aspects of SARS-CoV-2 242 infection, ranging from pathophysiology to epidemiology. 243

Overall, we observed a significant increase in antibody levels measured in the mucosal lining fluid of 245 the index cases, with a timing that is similar to what has previously been described for serum and 246 saliva 6,26,27 . Mucosal IgG and IgM antibody responses measured against the three viral antigens 247 correlated strongly with serum antibody levels, but were weaker for IgA, measured at 28-40 days PSO. 248 This has previously been described for saliva 26, 27, 31 . A key finding of this study is that the mucosal IgA 249 response against RBD showed the strongest relation to resolution of systemic disease symptoms. This 250 phenomenon has also been addressed by Butler et al. 32 in a smaller cohort (n=20). They found that 251 strong mucosal IgA responses against SARS-CoV-2 was related to neutralizing activity and that 252 elevated levels of mucosal neutralization were associated with mild and moderate symptoms. This 253 neutralizing activity of IgA has also been described in a bigger study that mainly focused on serum 33 . 254

Another study in one family showed spiking salivary IgA levels at the time of symptom resolution, 255 while serum antibody levels remained low. 3 Our larger study, including for the first time the dynamic 256 measurement of the lining fluid of the upper respiratory tract, clearly shows the relation of mucosal 257 antibodies with a decrease in symptom burden. Nevertheless, we did not measure neutralizing activity, 258

and found that other mucosal responses against S and RBD also contributed to a reduction of systemic 259 disease symptoms. Another significant finding was the negative correlation between viral load and 260 mucosal IgM against RBD and S, measured at study start, suggestive of a neutralizing role of mucosal 261

IgM, although other possible explanations, like pre-existing T-cell immunity cannot be excluded 34, 35 . Given their multimeric nature, IgM and IgA antibodies specific for RBD are likely to neutralize 267 SARS-CoV-2 particles and strong neutralizing capacity has been described previously for both 268 isotypes 33,38 . Therefore we propose that these antibodies should be included in the quality evaluation of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ;

Because we measured the mucosal response of three antibodies against three different antigens, we 275 were able to describe correlations between these antigen/isotype combinations. We found that there 276 was a coherent antibody production against S and RBD early in the infection. Correlations between S 277 and RBD with the N antigen were significantly less pronounced, and only emerged later in the 278 infection, mostly for IgG. This indicates that the antibody response to the nucleocapsid antigen follows 279 a different track after infection, than S and RBD, which was also seen in previous studies 26, 27, 31 . This 280 variation in the antibody response composition could be explained by the cross-reactivity with other 281 seasonal coronaviruses. Previous exposure with these coronaviruses could elicit a booster response 282 instead of a primary immune response during SARS-CoV-2 exposure, explaining the presence of IgG 283

and IgA and absence of IgM, which has the strongest response after primary exposure. Next to this, 284 the release of N-proteins requires the lysis of virally infected cells, as it encapsulates the viral RNA. 285

This could explain the difference in timing and the generally low mucosal antibody responses against 286 N, as all our participants developed mild disease. 287

The ability to measure the mucosal antibody response over a longer period of time in an easy, non-289 invasive manner allowed us to identify cases among the household members that were not picked up 290 by PCR-testing at a single timepoint only. When we performed the study, we were unable to collect 291 additional samples for viral PCR due to shortages in swabs and transport medium, limiting our ability 292 to fully study the dynamic interactions between viral infection and antibody responses, and calculate 293 the sensitivity of the antibody measurements in diagnosing infection in comparison to PCR. 294

We observed a very high proportion of cases among the household contacts (54.7%), which is much 295 higher than previously reported (11-37%) 39-41 . This can partly be explained by the fact that not all the 296 index cases were the primary case, due to the restricted PCR testing on specific risk-groups at the time 297 the study was performed. By using the households' primary case reporting, the secondary attack rate 298 (SAR) was lowered to 49.6%. The fact that we still find a higher SAR than described in previous 299 studies may be explained by the fact that almost all household transmission studies to date identified 300 cases based on PCR positivity only, and thus underestimate the true number of cases within a cluster. 301 PCR testing is prone to false negative results due to it being a one-time measurement, its dependency 302 on the time of sampling in relation to the infection, and the chance of errors during sample collection. 303

By combining PCR, serology and mucosal data, we were able to identify an additional 27 cases, 304

increasing the total number of contact cases by a third. Although we used the mucosal antibody levels 305

as an exploratory case-identification tool and used PCR and serology for most of the case 306 identifications, the majority of serum and PCR positive contacts also had mounted a mucosal antibody 307 response towards the end of the follow-up (Table S2 ). These results suggest that mucosal lining fluid 308 could be used as a non-invasive way to measure disease exposure in a community setting, and as a tool 309

to identify the primary case in a household. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint Children were initially thought to be play less of a role in SARS-CoV-2 infection and transmission, 312 because of a lower expression of ACE2 and the high frequency of asymptomatic infections compared 313 to adults [42] [43] [44] . This notion has been debated in research 11,45-48 , and is critical for making decisions 314 related to epidemic control measurements, like school-closure. In our study, we found that children 315 <12 years had a similar probability to become infected as adults. Almost half of the child cases in our 316 study were asymptomatic, their viral load at study start was similar to that of adults, and other studies 317 have shown that 40-80% of transmission events take place before symptom onset 49-51 . A study looking 318

at the viral shedding of asymptomatic, presymptomatic and symptomatic children did not find a 319 difference in viral shedding between these groups 52 . Together, these findings imply that children may 320 play a larger role in transmission of SARS-CoV-2 than is currently thought. A prospective cohort 321 study in which MLF samples are collected irrespective of symptom presentation would provide more is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Before the first home visit, all index cases of the family had a telephone interview, where they were 361 asked about their first day of symptom onset, whether they were in isolation from the rest of the 362 household, whether physical contact was restricted with other household members, whether they were 363 still symptomatic, and whether they thought they were the primary case in the household. Households 364 were visited within 1-2 days of a positive PCR in the index case. Following informed consent, 365 nasopharyngeal and oropharyngeal swabs were taken for viral PCR, as per diagnostic guidelines 53 . A 366 nasal mucosal lining fluid (MLF) sample was obtained from all participants by the use of the 367 Nasosorption™ FX·i nasal sampling device (Hunt Developments, UK). A synthetic absorptive matrix 368 (SAM) strip was gently inserted into the nostril of the participant and placed along the surface of the 369 inferior turbinate. The index finger was lightly pressed against the side of the nostril to keep the SAM 370 strip in place and to allow MLF absorption for 60 seconds, after which the SAM strip was placed back 371 in the protective plastic tube. Participants were instructed on how to self-sample MLF at home. 372

Finally, participants were asked about their symptoms of that day. 373

Participants were followed up for approximately 28 days, starting on the day of the first home visit 374 (day 0) and ending on the last home visit (day 28-33). This range in the last visit was due to logistical 375 difficulties during the summer holidays; 14 index cases were visited on their day 29, three on day 30, 376 five on day 31, four on day 32 and one on day 33. All particpants registered their symptoms for 28 377 days. During follow-up, clinical symptoms were registered three times daily and MLF was collected at 378 three different study days via self-sampling. For the index case, MLF was collected on day 0, 3, 6 and 379 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint 28-33 and for the household contacts this was on day 0, 7, 14 and 28-33 (Figure 1c) . Self-sampled 380 MLF samples were stored in biosafety bags in the participants' own freezer (temperature around -20 381

At the final home visit, MLF samples were picked up and transported to the Radboudumc on dry ice, 383

where it was stored at -80°C until further testing. For antibody analysis, Nasosorption™ FX·i nasal 384 sampling devices were thawed on ice, after which the synthetic adsorptive matrix (SAM) was removed 385 using sterile forceps. The SAM was placed in a spin-X filter Eppendorf tube with 300uL of elution 386 buffer (PBS/1% BSA) for a minimum of 10 minutes, followed by centrifugation at 16000xg for 10 387 minutes at 4°C. To prevent unspecific binding, the spin-X filter columns were pre-incubated with the 388 blocking buffer for 30 minutes.The filter cups were then removed from the Eppendorf tubes using 389 sterile forceps. To inactivate live SARS-CoV-2, the eluate was incubated for a minimum of 45 390 minutes at 56 °C, spun down, aliquotted and stored at -20°C for further testing. 391

Finger-prick blood (~0.3 ml) was collected from all participants consenting to the finger-prick at day 392 28 by the use of a sterile disposable lancet device (BD Microtainer Lancet) and a sterile capillary tube. 393

Blood samples were kept at room temperature until processing at the Radboudumc laboratory site, 394 after which serum was stored at -20°C until further testing. 395

All collected symptom diaries were digitalized into Castor EDC, clinical trial software for electronic 396 data capture and clinical data management. 397 398

Presence or absence of SARS-CoV-2 and viral copy number per ml was determined on the combined 401 nasopharyngeal and oropharyngeal swab, using a PCR protocol that was developed at the 402 Radboudumc Medical Microbiology Laboratory. Nasopharyngeal and oropharyngeal swabs were 403 collected in GLY medium and stored at -80°C untill processing. Samples were thawed, vortexed and 404 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10. 1101 /2021 For antibody analysis, a fluorescent-bead-based multiplex immunoassay (MIA) was developed. The 417 stabilized pre-fusion conformation of the ectodomain of the Spike protein (amino acids 1 -1,213) 418 fused with the trimerization motif GCN4 (S-protein) and the receptor binding domain of the S-protein 419 (RBD) as previously described by Wang C. et al. 54 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint resulted in a set of 23 symptoms, which were categorized into three categories, i.e. respiratory 454

chest pain, sneezing, nose bleeding, pain when breathing, coughing with mucus, dyspnoea, sore throat, 456 loss or change of taste/smell (dysnosmia), coughing, and rhinorrhoea. SDS includes dizziness, 457 headache, fever, temperature, chills, joint pain, muscle pain, swollen lymph nodes and low appetite. 458 GS includes vomiting, diarrhoea, and nausea. Because fatigue was reported in almost all cases, we did 459 not categorize it into one of the symptom categories. 460 461

For analysis of SARS-CoV-2 exposure within households, we categorized the household contacts into 463 cases and controls. Cases were defined as being either PCR positive at study start and/or seropositive 464 for IgA, IgG or IgM against S at the end of follow-up. PCR positivity was set on a Ct value<36, which 465 corresponds to a viral load of at least 10 3 copies/ml extracted sample. The seroconversion threshold 466 was based on the mean + 2*SD of the historic negative control samples, which were collected before 467 SARS-CoV-2 was introduced in the Netherlands. Additionally, we used a Naïve Bayesian 468 probabilistic model (R-package "naivebayes", with prior probabilities derived as the class proportions 469 for the training set, and Laplace smoothing set at 1) to identify cases within the PCR/seronegative and double checked with the paper records by two members of the research team. All statistical 479 analyses were performed using the Rstudio environment, with libraries 'stats' (hypothesis tests and 480 correlations), "naivebayes" for the naïve Bayes classification, "lme4" 56 , "lmerTest" 57 for mixed-481 effects modelling and associated p-values, and "survival" 58 for Kaplan-Meier survival analysis. The 482 libraries "survminer" and "ggplot2" were used for visualization. Changes in serum or mucosal 483 antibodies compared to negative controls were tested using a two-tailed paired Wilcoxon signed rank 484 test, and then corrected for multiple testing with the Benjamini-Hochberg method 59 . Statistical 485 parameters including the sample sizes, measures of distribution, and p-value thresholds for 486 significance are reported directly in the figures and figure legends. In order to determine if a sample 487 was seropositive for a given combination of antigen and antibody isotype, a cut-off value (mean + 2 488 standard deviations) was calculated from the negative control samples. Samples above this threshold 489 were classified as seropositive for that antigen and isotype combination. Samples that were 490 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint seropositive for any of the antibodies tested were classified as such ("anySero", Figure 2A) . Where 491 correlations are presented, the spearman correlation coefficient and associated p-value were calculated. 492

The time at which a subject became symptom-free was calculated as the last day that individual 493 showed symptoms for that category, plus one day. The probability of becoming symptom-free was 494 estimated using Kaplan-Meier's method, and the hypothesis testing was performed using log-rank test. 495

In order to estimate the effect of patient characteristics and antibodies on symptoms over time, we 496 constructed a mixed-effects model. For each subject and for each timepoint, we added together the 497 number of complaints per symptom category. We specified a mixed-effects model per symptom 498 category with symptoms as the response and time since symptom onset (POS), age, and sex, as 499 explanatory variables. We also added POS and Sample_ID as random effects. The formula for the 500 model (in R notation): Estimates for the covariates, as well as 95% confidence intervals and p-values (Satterthwaite's 510 approximation to degrees of freedom) were extracted and plotted. 511

This study was funded by the Laboratory of Medical Immunology, Radboud university medical center. 514

The data and R-code that support the findings of this study are available from the corresponding 517 author upon reasonable request. 

There are no competing interests to be declared. 527 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ;

households, sample sizes, and study outcomes. We initially contacted 97 index cases that were tested 541 positive for SARS-CoV-2. After exclusion of cases that did not meet the inclusion criteria or did not 542 consent, 50 index cases and their household contacts (N=137)were recruited. Mucosal lining fluid 543 (MLF) antibodies were analysed as a primary outcome in both indexes and household contacts. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi. org/10.1101 org/10. /2021 with the controls with the Wilcoxon-signed rank test. A non-parametric Loess curve is shown as red 576 line to visualize the trend over time. Measurements from the same individual are connected with a 577 grey line. c) Antibody measurements within the depicted timeframes were correlated with each other. response was specified as the number of symptoms on a given day, and explanatory fixed effects 588 variables were: day since symptom onset, age, and sex. Time since symptom onset was also specified 589 as a random slope, and Sample ID as a random intercept. A significant effect of age (p = 0.0165) was 590 demonstrated for RS. Predicted symptom values from the model are plotted against index case age 591 with 95% confidence interval bands. c) Longitudinal mucosal antibody measurements were added as 592 fixed effect variables in a univariate fashion to the MEM from b). The predicted change in symptoms 593 per unit increase of antibody signal is presented with 95% confidence intervals, and p-values for the 594 association are plotted on the right (* p <0.05; ** p<0.01; *** p<0.001). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint are presented for comparison. A non-parametric loess curve is shown as a red (primary cases) and a 613 blue (non-primary cases) line to visualize the trend over time. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. We initially contacted 97 index cases that were tested positive for SARS-CoV-2. After exclusion of cases that did not meet the inclusion criteria or did not consent, 50 index cases and their household contacts (N=137)were recruited. Mucosal lining fluid (MLF) antibodies were analysed as a primary outcome in both indexes and household contacts. Secondary analyses (correlation of MLF antibodies with viral load and symptoms, serology, estimation of SARS-CoV-2 exposure) were performed. b) Study timeline, with respect to the number of hospitalizations due to COVID-19 over time and COVID-19 control measures in the Netherlands60,61. The first home visit was conducted at the peak of hospitalizations at March 26, and the last visit was one day after the reopening of primary schools, at May 13. c) Overview of the study design and measurements. Home visits were initiated after the index was tested positive for SARS-CoV-2 by PCR, to collect naso-and oropharyngeal swabs for viral load determination as well as nasal MLF samples. Subsequent MLF samples were collected and stored by the participants, who also completed a daily symptom survey. At the end of the study, blood samples were collected for serological analyses. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint mixed-effect model (MEM) was fit to the data per symptom group. The response was specified as the number of symptoms on a given day, and explanatory fixed effects variables were: day since symptom onset, age, and sex. Time since symptom onset was also specified as a random slope, and Sample ID as a random intercept. A significant effect of age (p = 0.0165) was demonstrated for RS. Predicted symptom values from the model are plotted against index case age with 95% confidence interval bands. c) Longitudinal mucosal antibody measurements were added as fixed effect variables in a univariate fashion to the MEM from b). The predicted change in symptoms per unit increase of antibody signal is presented with 95% confidence intervals, and p-values for the association are plotted on the right (* p <0.05; ** p<0.01; *** p<0.001).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint Identification of household contact cases and assessment of their mucosal SARS-CoV-2 antibody responses. a) Contact cases were classified into case or non-case first by their PCR result on enrolment, followed by seroconversion for either IgM, IgG or IgA against the S-protein, and mucosal antibody levels for either IgM, IgG or IgA against the S-protein at the end of the follow-up. The PCR positive threshold was set at a Ct value <36. The seroconversion threshold was based on the mean + 2*SD of the log2-transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal antibodies against S, we used a naive Bayes model that was trained by the mucosal antibody measurements of the positive study participants (cases) and the pre-SARS-CoV-2 control samples (controls). b) Contacts were classified by their household as either the primary (N=9) or a non-primary (N=58) case, based on time of symptom onset. Mucosal antibody responses of the primary household contact cases collected at d0 were correlated with viral load. Spearman correlations were calculated, * p <0.05, ** p<0.01, *** p<0.001. p-values of borderline significant tests are reported directly in the figure. c) IgM, IgG and IgA antibody responses against Spike protein (S), receptor binding domain (RBD) and nucleocapsid (N), measured in mucosal lining fluid. Data are plotted relative to the time of symptom onset of the index case in the respective household, and pre-SARS-CoV-2 control samples are presented for comparison. A non-parametric loess curve is shown as a red (primary cases) and a blue (non-primary cases) line to visualize the trend over time.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint Sixteen out of 33 primary school-age children (1-12y) were infected (48%), 13 out of 23 children aged 13-18y (56%), 27 out of 50 adults aged 19-49 years (54%) and 19 out of 31 contacts older than 50 years (61%). b) Proportion of asymptomatic disease among household cases (N=75) at study enrolment within each age category. Seven of the children below 12 years were asymptomatic (44%), two of the children up to 18 years (15%), seven of the adults up to 49 years (28%) and two of the contacts older than 50 years (11%). c) The correlation between the total number of reported symptoms and the age of the infected household contacts. Pearson's correlation and significance is depicted in the figure. The shape of the datapoints represents the method by which a contact was classified as a case and the color of the datapoints shows the viral load at study start.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.02.21250910 doi: medRxiv preprint

Early Release-Characteristics and Timing of Initial 680 Virus Shedding in Severe Acute Respiratory Syndrome Coronavirus 2

Transmission of SARS-COV-2 infections in households-682

Immune responses to SARS-CoV-2 in three children of 685 parents with symptomatic COVID-19

Virological assessment of hospitalized patients 687 with COVID-2019

Clinical Course and Molecular Viral Shedding Among Asymptomatic 689 and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the 690 Republic of Korea

Temporal profiles of viral load in posterior oropharyngeal 692 saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational 693 cohort study

Characteristics of and Important Lessons From the Coronavirus Disease 695 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center 696 for Disease Control and Prevention

Clinical characteristics of asymptomatic and symptomatic 698 patients with mild COVID-19

Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review

Epidemiologische situatie COVID-19 in Nederland: Rijksinstituut voor Volksgezondheid 702 en Milieu

Asymptomatic transmission, the Achilles' heel of current 704 strategies to control COVID-19. Mass Medical Soc; 2020. 705 12. WHO. Public health surveillance for COVID-19 WHO

Longitudinal symptom dynamics of COVID-19 infection in 709 primary care

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 711 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

South Africa, and the UK. The Lancet 2020

Safety and efficacy of the BNT162b2 mRNA covid-19 714 vaccine

The nucleocapsid protein of SARS-CoV-2: a target for 716 vaccine development

Heterogeneous antibodies against SARS-CoV-2 718 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

Antibody responses to SARS-CoV-2 in patients of novel 721 coronavirus disease 2019

Spectrum of innate and adaptive immune 723 response to SARS CoV 2 infection across asymptomatic, mild and severe cases; a longitudinal cohort 724 study

Differences in antibody kinetics and functionality 726 between severe and mild SARS-CoV-2 infections

Serum-IgG responses to SARS-CoV-2 after mild and 728 severe COVID-19 infection and analysis of IgG non-responders

SARS-CoV-2 infection induces robust, neutralizing 730 antibody responses that are stable for at least three months. medRxiv 2020

Intranasal vaccination of recombinant adeno-associated virus 732 encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) 733 spike protein induces strong mucosal immune responses and provides long-term protection against 734 SARS-CoV infection

Mucosal Immunization with Surface-Displayed Severe Acute 736 Respiratory Syndrome Coronavirus Spike Protein on <em>Lactobacillus casei</em> Induces 737 Neutralizing Antibodies in Mice

COVID-19 serology at population scale: SARS-CoV-2-739 specific antibody responses in saliva

Persistence of serum and saliva antibody responses to SARS-741

CoV-2 spike antigens in COVID-19 patients

Systemic and mucosal antibody secretion specific to 743 SARS-CoV-2 during mild versus severe COVID-19

Longitudinal evaluation and decline of antibody responses 745 in SARS-CoV-2 infection

Clinical and epidemiological characteristics of 747 1,420 European patients with mild-to-moderate coronavirus disease 2019

Detection of antibodies to the SARS-CoV-2 spike 750 glycoprotein in both serum and saliva enhances detection of infection

Features and Functions of Systemic and Mucosal 752

Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. medRxiv 2020

IgA dominates the early neutralizing antibody response 754 to SARS-CoV-2

SARS-CoV-2-specific T cell immunity in cases of 756 COVID-19 and SARS, and uninfected controls

Selective and cross-reactive SARS-CoV-2 T cell epitopes in 758 unexposed humans

Characteristics and serological patterns of COVID-19 convalescent 760 plasma donors: optimal donors and timing of donation

Convalescent plasma in Covid-19: Possible 762 mechanisms of action

Major role of IgM in the neutralizing activity of 764 convalescent plasma against SARS-CoV-2. bioRxiv 2020

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of 766 their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet Infectious Diseases

What do we know about SARS-CoV-2 transmission? A 769 systematic review and meta-analysis of the secondary attack rate, serial interval, and asymptomatic 770 infection

Transmission dynamics of COVID-19 in 772 household and community settings in the United Kingdom. medRxiv 2020. 773 42. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 774 in children and adults

Epidemiology of COVID-19 among children in China

COVID-19 epidemic: disease characteristics in children

Transmission of SARS-CoV-2 following exposure in school 780 settings: experience from two Helsinki area exposure incidents

Clinical Characteristics and Viral RNA Detection in Children 782

With Coronavirus Disease 2019 in the Republic of Korea

COVID-19 in children: the link in the transmission chain. The Lancet 784 Infectious Diseases

COVID-19 transmission and children: the child is not to blame

Evidence for transmission of COVID-19 prior to 788 symptom onset

Contact tracing assessment of 790 COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after 791 symptom onset

The implications of silent transmission for the 793 control of COVID-19 outbreaks

Clinical characteristics and viral RNA detection in children 796 with coronavirus disease 2019 in the Republic of Korea

SARS-CoV-2-Specific Antibody Detection for 802 Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. The 803

Fitting linear mixed-effects models using lme4

lmerTest package: tests in linear mixed effects 807 models

The Cox model. Modeling survival data: extending the Cox 809 model

Controlling the False Discovery Rate: A Practical and Powerful 811 Approach to Multiple Testing